AbbVie strikes $10.9 billion deal for Apogee Therapeutics
Apogee Therapeutics, Inc.
Nuvalent, Inc. Class A
آبفي
ريجينيرون
غلاكسو سميث كلاين
Apogee Therapeutics, Inc. APGE | 0.00 | |
Nuvalent, Inc. Class A NUVL | 0.00 | |
AbbVie, Inc. ABBV | 0.00 | |
Regeneron Pharmaceuticals, Inc. REGN | 0.00 | |
GlaxoSmithKline plc Sponsored ADR GSK | 0.00 |
June 22 (Reuters) - AbbVie ABBV.N will acquire biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.